Oral Drugs Against COVID-19: Management of Drug Interactions With the Use of Nirmatrelvir/Ritonavir.
Background: Five-day oral therapies against early COVID-19 infection have recently been conditionally approved in Europe. In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administr...
| Publicado en: | Deutsches Ärzteblatt International Vol. 119; no. 15; pp. 263 - 273 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Deutscher Aerzte-Verlag GmbH
4/15/2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |